Pharma’s Upcoming Messaging Battles In US Pricing Debate Foreshadowed In CBO Report

Our infographic offers the top takeaways from Congressional Budget Office report that says lower drug prices would decrease industry’s spend on research and development, while rejecting claim that costs of R&D set or impact a particular medicines price.

Pills in Capitol Hill forecast
The CBO report probably won't change the forecast for Rx pricing legislation, but it will definitely hang in the air.

A New Congressional Budget Office report on research and development in the pharmaceutical industry is an important reminder to industry of the upcoming policy fights coming its way in Washington, DC.

The report is largely a 101-backgrounder on the industry and how US policies – from Food and Drug Administration...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access